Genetic Technologies (ASX:GTG) Total Liabilities: A$4.36 Mil (As of Jun. 2024)


What is Genetic Technologies Total Liabilities?

Genetic Technologies ASX:GTG Total Liabilities is A$4.36 Mil as of Jun. 2024.

Genetic Technologies's Total Liabilities for the quarter that ended in Jun. 2024 was A$4.36 Mil.

Genetic Technologies's quarterly Total Liabilities declined from Dec. 2023 (A$3.66 Mil) to Mar. 2024 (A$0.00 Mil) but then increased from Mar. 2024 (A$0.00 Mil) to Jun. 2024 (A$4.36 Mil).

Genetic Technologies's annual Total Liabilities declined from Jun. 2022 (A$4.37 Mil) to Jun. 2023 (A$3.69 Mil) but then increased from Jun. 2023 (A$3.69 Mil) to Jun. 2024 (A$4.36 Mil).

Genetic Technologies Total Liabilities Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Total Liabilities Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.64 1.44 4.37 3.69 4.36

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 3.66 0.00 4.36 0.00

Genetic Technologies Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Genetic Technologies's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.195+(0.023+0.056
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.082+0+0)
=4.36

Total Liabilities=Total Assets (A: Jun. 2024 )-Total Equity (A: Jun. 2024 )
=6.187-1.83
=4.36

Genetic Technologies's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.195+(0.023+0.056
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.082+0+0)
=4.36

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=6.187-1.83
=4.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of A$4.36 Mil mean?
Genetic Technologies (ASX:GTG) has a Total Liabilities of A$4.36 Mil as of Jun. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Genetic Technologies and its competitors.
Is Genetic Technologies' Total Liabilities too high?
Genetic Technologies' current Total Liabilities is A$4.36 Mil.
How does Genetic Technologies' Total Liabilities compare to LDDD and NOTV?
Genetic Technologies' Total Liabilities of A$4.36 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Genetic Technologies and its competitors. Genetic Technologies's current Total Liabilities is A$4.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current Total Liabilities of A$4.36 Mil. The current Total Liabilities is A$4.36 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current Total Liabilities is A$4.36 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.